During the ENDO 2024 conference in Boston, USA, endocrinologists from the Postgraduate Institute of Medical Education and Research (PGIMER) in Chandigarh were recognized. In June 2024, approximately 6000 endocrinologists, doctors, and fellows from around the globe gathered at this esteemed event to talk about the most recent developments in the field of endocrinology.
PGIMER’s Head of the Department of Endocrinology, Prof. Sanjay K. Bhadada, was presented with the Laureate Award for Outstanding Mentor. This honor was given to him in appreciation for his outstanding contributions to the study of metabolic bone diseases, such as osteoporosis, primary hyperparathyroidism, and uncommon bone illnesses, as well as his mentoring in this area. Prof. S. Bhasin of Harvard University’s Brigham and Women’s Hospital nominated Prof. Bhadada for this honor.
Prof. Bhadada was invited to represent India at the Global Endocrinology Leaders Meeting during the conference in addition to being given this honor. Here, he talked about the particular difficulties that the endocrinology field in India faces. Additionally, Prof. Bhadada gave an oral presentation on his innovative study, which was chosen for oral presentation, on the microarchitecture and bone health of postmenopausal women with type 2 diabetes mellitus employing sodium-dependent glucose cotransporters (SGLT2i). Moreover, he was recognized recently for his work on insights from a rare metabolic bone disease registry, receiving the Prof. Maria Lusia Bianchi Award at the 51st European Calcified Tissue Society annual meeting in Marseille, France.
At the ENDO 2024 conference, Dr. Liza Das of PGIMER was also honored with a Young Investigator Award. Her study on pituitary abnormalities was recognized with this honor in the young faculty category. Dr. Das discussed her research on the effects of oral glucagon-like peptide 1 (GLP1) analogue on bone microarchitecture in patients with type 2 diabetes mellitus and obesity as well as metabolic-dysfunction associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD). This study demonstrates how GLP1 analogs may be used to treat MASLD and enhance bone health in people with diabetes and obesity.
The achievements of Dr. Das go beyond ENDO 2024. She was the recipient of the 18th Annual Pituitary Congress in Chicago’s Early Career Investigator Prize in Pituitary Disease last year. In the Indian setting, Sheehan’s syndrome is an uncommon cause of hypopituitarism. Her award-winning work evaluated the long-term cardiac and liver consequences in patients with hypopituitarism related to this illness.
The fact that Dr. Das and Prof. Bhadada are acknowledged in such prestigious international venues highlights the important contributions that Indian endocrinologists have made to the world’s medical community. Their innovative studies, commitment to patient care, and mentoring further advance our knowledge of and ability to manage complicated endocrine illnesses.
SOURCE:
HINDUSTAN TIMES
